Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932662 | 0.85 | CYP2C19 (0.61) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL6647402 | 0.84 | TSHR (0.59) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL76204 | 0.83 | CYP2C19 (0.64) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL30643815 | 0.83 | CYP2C19 (0.64) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL8934567 | 0.83 | ALDH1A1 (0.58) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL28532343 | 0.82 | ALDH1A1 (0.60) | CYP2C19CYP1A2MAPTALDH1A1MEN1 | |
| SCHEMBL1369959 | 0.82 | CYP2C19 (0.62) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL27861234 | 0.82 | CYP2C19 (0.62) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL2527458 | 0.82 | CYP2C19 (0.62) | CYP2C19CYP1A2MAPTALDH1A1GAA | |
| SCHEMBL1369963 | 0.82 | CYP2C19 (0.62) | CYP2C19CYP1A2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1092027-B1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | JONES DAVID S | 2006-06-29 | — | — | US | disclosed |
| US-6858210-B1 | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same | LA JOLLA PHARMACEUTICAL CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | MARQUIS DAVID M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | JONES DAVID S (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1183230-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000075105-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | CYP2C19 1074/4885CYP1A2 1519/4885MAPT 2550/4885 |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | SHBG, DAO, DNPEP | CYP2C19 1055/4885CYP1A2 1939/4885MAPT 3182/4885 |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | CYP2C19 1074/4885CYP1A2 1519/4885MAPT 2550/4885 |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | PLTP, PA2G4, PAG1 | CYP2C19 4780/4885CYP1A2 4395/4885MAPT 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.